The Netherlands Pharmacovigilance Centre Lareb identifies risks associated with the use of medicines in daily practice and is the Knowledge Centre for adverse drugs reactions (ADRs).
Lareb collects 20.000 to 25.000 reports of adverse drug reactions yearly. Analysis of reports lead to signals about adverse drug reactions. These signals are reported to and reviewed by the Dutch Medicines Evaluation Board (MEB). This intensive cooperation supports the MEB in its decisions with regard to its role in pharmacovigilance in the Netherlands and Europe.
The Teratology Information Service (TIS) of Lareb is the knowledge centre on safety of drugs used before and during pregnancy and during lactation. The Dutch Pregnancy Drug Register (“Moeders van Morgen”) monitors the use and safety of drugs during pregnancy and lactation.
Monitoring of the safety of drug use during pregnancy is a special topic of interest in PV and requires a distinct approach. To support other pharmacovigilance (PV) centres in the practice of PV specific to the use of drugs during pregnancy a Pregnancy PV toolkit is developed.
Lareb is an independent foundation and is funded by the MEB and the Ministry of Health.
The Netherlands Pharmacovigilance Centre Lareb has special interest in education and patient reporting in pharmacovigilance.
Please have a look at our annual report in numbers: